PDS Biotechnology Corporation

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PDS Biotechnology advances oncology pipeline with promising trial results

PDS Biotechnology's strategic focus on oncology pipeline advancement, strong interim trial results, and financial stability position the company for continued growth and clinical success.
While facing financial challenges and operational complexities, the company's proactive approach to trial designs, regulatory engagements, and commercialization strategies offer promising opportunities for future development.
Overall, PDS Biotechnology's performance in 2022 reflects a balance of achievements, challenges, and opportunities, underscoring a commitment to innovation and clinical progress in the oncology space.

PDS Biotechnology reports Q1 loss, progresses promising cancer therapies

PDS Biotechnology's Q1 performance reflects ongoing investment in clinical development.
Strengths lie in innovative therapies, upcoming Phase 3 trial, and manufacturing progress.
Challenges include financial losses, competition, and meeting trial milestones.
Opportunities exist in clinical advancements, partnerships, market demand, and investor confidence.

PDS Biotechnologies reports Q2 loss, progresses in clinical trials

PDS Biotechnologies faces increased expenses but maintains strong funding for future operations.
Progress in clinical programs and upcoming milestones provide growth opportunities.
Challenges include trial requirements and enrollment timelines, but company is managing well.

PDS Biotechnology reports promising cancer therapy results amidst financial challenges

PDS Biotechnology demonstrates clinical success with PDS0101 and PDS01ADC, while facing financial pressures and operational challenges.
Strategic strengths in oncology programs and proactive clinical development position the company for growth and potential partnerships.
Opportunities lie in diversification with PDS0202, expanding the pipeline, and leveraging positive data from upcoming investigator-initiated trials.
Navigating financial challenges, operational complexities, and maximizing therapeutic potential will be key for PDS Biotechnology's future success.

PDS Biotechnology reports Q4 loss, focuses on innovative cancer trials

PDS Biotechnology's Q4 2023 Earnings Call highlighted financial performance, strategic focus on innovative clinical trials, and promising data-driven decisions.
The company's strengths lie in its collaborations with the National Cancer Institute, advancements in Phase II programs, and a healthy cash balance supporting future funding.
Challenges include managing rising operating expenses, delivering on trial outcomes, and navigating market competition, while opportunities exist in establishing leadership in cancer therapies and attracting investors.
Overall, PDS Biotechnology's emphasis on data-driven strategies, strong financial position, and commitment to advancing cancer treatments position it for potential growth and success in the biopharmaceutical industry.

PDS Biotechnology reports Q3 loss, optimistic on Versamune HPV potential

PDS Biotechnology Corporation's Q3 2024 performance reflected increased R&D expenses and strategic trial design modifications.
Despite financial challenges and competitive pressures, the company remains optimistic about the potential of Versamune HPV.
Opportunities lie in advancing the VERSATILE-003 trial, leveraging positive feedback, and addressing unmet medical needs in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that the initial safety data from its VERSATILE-002 study has been accepted for presentation at the 2022 Multidisciplinary Head and Neck Cancers Symposium being held February 24-26, 2022, at the JW Marriott Phoenix Desert Ridge Resort and Spa, Phoenix, AZ.

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

FLORHAM PARK, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company's new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS Biotech.

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Institutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes Institutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2021 Results - Earnings Call Transcript

FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended September 30, 2021 and provide a business update on its conference call today.

PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results

FLORHAM PARK, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced an agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, PDS0202, a universal flu vaccine candidate.

PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the company's Chief Medical Officer, Dr. Lauren V. Wood, will be presenting at the upcoming 2021 International Head and Neck Cancer Conference hosted by Cardiff, NHS Wales and The Swallows Head & Neck Cancer Support Group.

PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference

PDS Biotechnology Corporation (NASDAQ: PDSB) has temporarily suspended recruitment in the National Cancer Institute (NCI)-led Phase 2 trial of PDS0101 combo trial in advanced HPV cancers The issue is not specific to the PDS0101 trial and is unrelated to the triple combination's safety or efficacy concerns.

PDS Biotech Pauses Recruitment In PDS0101 Combo Cancer Trial

Temporary administrative suspension of recruitment – no safety or efficacy concerns related specifically to the novel PDS0101-based combination study Temporary administrative suspension of recruitment – no safety or efficacy concerns related specifically to the novel PDS0101-based combination study

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, will release financial results for the third quarter of 2021 on Wednesday, November 10, 2021, before the market opens. Following the release, management will host a conference call to review the company's financial results and provide a business update.

PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results

FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced the completion of enrollment for the first stage of the checkpoint inhibitor naïve arm of its VERSATILE-002 Phase 2 study for the treatment of recurrent and/or metastatic human papillomavirus (HPV16)-associated head and neck cancer. 90% of HPV-associated head and neck cancers are reported to be caused by HPV16 as reported by a study published in the Journal of Clinical Medicine.

PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

No dose limiting toxicities observed in initial group of 12 patients No dose limiting toxicities observed in initial group of 12 patients

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

AMC Entertainment

Vinco Ventures

CPI Card Group

Support.com

Were these penny stocks on your list this year? The post Best Penny Stocks To Buy In 2021?

Best Penny Stocks To Buy In 2021? 5 That Turned $2,500 Into $26,000

FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.

PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2021 Results - Earnings Call Transcript

FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today.

PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

New York, New York--(Newsfile Corp. - July 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of PDS Biotechnology Corporation (NASDAQ: PDSB) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/pds-biotechnology-corporation-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of PDS Biotechnology Corporation - PDSB

FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, was added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, according to the FTSE Russell website.

PDS Biotechnology Joins Russell Microcap® Index

NetScientific PLC (LON:NSCI) said its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB), has closed its underwritten public offering of shares. The shares were offered at US$8.50 a pop.

NetScientific gives further backing to PDS Biotechnology

The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by over 15% during intraday trading. This is why it happened.

PDSB Stock Price Increases Over 15%: Why It Happened

FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,088,235 shares of common stock (inclusive of the 794,117 shares that were sold pursuant to the underwriter's full exercise of its option to purchase additional shares of common stock) at a public offering price of $8.50 per share. Certain insiders, including certain members of the Company's board of directors and executive officers, purchased shares of PDS Biotech common stock in the offering.

PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

WH Ireland applauded the progress of NetScientific PLC (LON:NSCI) investee company PDS Biotechnology Corporation (NASDAQ: PDSB), which has unveiled plans to raise US$45mln. The broker said the latest funding round underlined investor confidence in the prospects for PDS and interest in its immuno-oncology platform, Versamune.

News for PDS Biotechnology Corporation Stock (PDSB)